Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR236553/REGN727 versus ezetimibe added to statin therapy in high cardiovascular risk hypercholesterolemia
2011-004130-34Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing REGN727 add-on to maximally tolerated statin with Ezetimibe add-on to maximally tolerated statin (2 arms). Primary endpoint: Percent change in LDL-C. Started Jul 2012; status: completed.
02
Drugs
alirocumabezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2011-004130-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004130-34.